Dasatinib inhibits progenitor cell proliferation from polycythaemia vera

European Journal of Clinical Investigation

Volumn 38, Issue 8, 2008, Pages 578-584

  Wappl, M ^a   Jaeger, E ^a   Streubel, B ^a   Gisslinger, H ^a   Schwarzinger, I ^a   Valent, P ^a   Oehler, L ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Dasatinib; JAK2V617F; Polycythaemia vera; Progenitor cell

Indexed keywords

DASATINIB; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 3;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CELL GROWTH; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ERYTHROID CELL; FEMALE; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STEM CELL;

ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROID PRECURSOR CELLS; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MYELOID PROGENITOR CELLS; POLYCYTHEMIA VERA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAZOLES;

EID: 47649112561     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2008.01982.x     Document Type: Article

References (21)

1. Siebolts U, Ates M, Spitz R, Thiele J, Wickenhauser C. Quantification of clonal hematopoiesis in polycythemia vera. Virchows Arch 2005 447 : 947 53.
2. Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006 108 : 1377 80.
3. Ohler L, Geissler K, Hinterberger W. Diagnostic and prognostic value of colony formation of hematopoietic progenitor cells in myeloid malignancies. Wien Klin Wochenschr 2003 115 : 537 46.
4. Person TC. Evaluation of diagnostic criteria in polycythemia vera. Semin Hematol 2001 38 (Suppl. 2 21 4.
5. Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K et al. The World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders. Semin Thromb Hemost 2006 32 : 307 40.
6. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002 101 : 2292 302.
7. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005 7 : 387 97.
8. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005 352 : 1779 90.
9. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005 365 : 1054 61.
10. Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006 108 : 1377 80.
11. V617F mutation. Exp Hematol 2007 35 : 32 7.
12. Oehler L, Jaeger E, Eser A, Sillaber C, Gisslinger H, Geissler K et al. Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro. Blood 2003 102 : 2240 2.
13. Silver RT. Imatinib mesylate (Gleevec (TM) reduces phlebotomy requirements in polycythemia vera. Leukemia 2003 17 : 1186 7.
14. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004 305 : 399 401.
15. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K et al. Discovery of N-(2-chloro-6-methyl- phenyl) -2-(6-(4-(2-hydroxyethyl) -piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumour activity in preclinical assays. J Med Chem 2004 47 : 6658 61.
16. Agis H, Jager E, Doninger B, Sillaber C, Marosi C, Drach J et al. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells. Eur J Clin Invest 2006 36 : 402 8.
17. Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic cell lineages by JAK2V617F mutation in polycythemia vera. Blood 2006 108 : 3128 34.
18. Oehler L, Födinger M, Köller M, Kollars M, Reiter E, Bohle B et al. Interleukin-10 inhibits spontaneous CFU-GM growth from human peripheral blood mononuclear cells by suppression of endogenous GM-CSF release. Blood 1997 89 : 1147 53.
19. Luo FR, Yang Z, Camuso A, Smykla R, McGlinchey K, Fager K et al. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res 2006 23 : 7180 6.
20. Cotes PM, Dore CJ, Yin JA, Lewis SM, Messinezy M, Pearson TC et al. Determination of serum immunoreactive erythropoietin in the investigation of erythrocytosis. N Engl J Med 1986 315 : 283 7.
21. Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S, Van Etten RA. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE 2006 1 : e18.